Exploring plasma p-tau217: a game-changer in Alzheimer’s trials

2024-07-31

Welcome to the VJSounds podcast, presented by the Video Journal of Dementia. In this episode, we dive into the latest advancements in Alzheimer's disease (AD) biomarkers, focusing on the diagnostic and predictive potential of plasma p-tau217. As an alternative to traditional PET assessment, blood-based biomarker detection has the potential to provide a time-efficient, cost-effective strategy for pre-screening and treatment monitoring in AD clinical trials. Although the widespread use of blood-based...

As an alternative to traditional PET assessment, blood-based biomarker detection has the potential to provide a time-efficient, cost-effective strategy for pre-screening and treatment monitoring in AD clinical trials. Although the widespread use of blood-based biomarkers in clinical practice remains to be seen, they also hold promise in expediting diagnostic/prognostic procedures for AD.

In this episode, we are joined by renowned researchers who discuss their work to test and validate p-tau217, both as a tool for clinical trials and for use in daily practice.

With Marco Bucci, PhD, Karolinska Institutet, Stockholm, Sweden; Suzanne
Schindler, MD, PhD, Washington University in St. Louis School of Medicine,
St. Louis, MO; Pamela Lukasewicz Ferreira, PhD, University of Pittsburgh,
Pittsburgh, PA; and Lyduine Collij, PhD, Lund University, Lund, Sweden.

Comments (3)